All News
In a small study of 14 rectal cancer patients, researchers at Memorial Sloan Kettering Cancer Center published results where 100% of the 12 patients who completed treatment went into remission.
The combination of Opdivo plus Yervoy in addition to chemotherapy demonstrated additional benefits in patient populations who usually have poor prognoses.
Data presented in bladder and pancreatic cancer at ASCO underscore the company’s vision of using NK cells and T cells to target difficult-to-treat cancers.
A combination study of CG Oncology’s oncolytic immunotherapy and a checkpoint inhibitor is showing promise.
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
GSK’s MMR vaccine is only the second to be approved in the United States for protection against measles, mumps and rubella. The first, licensed to Merck, was approved in 1971.
The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.
Ibrance, a first-line treatment for ER+, HER2 - metastatic breast cancer, did not improve the overall survival rate in patients. Read on to know more.
Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.
The early data demonstrated a favorable safety profile and encouraging indications of clinical activity. BNT122 is being developed in multiple solid tumor indications.
The study revealed that Yescarta was both safe and effective in adult patients regardless of race and ethnicity.
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology’s annual meeting.
Well-known for its neurological drug development programs, Alkermes has firmly planted its flag as an oncology company at ASCO. Alkermes Head of Oncology Jessicca Rege spoke with BioSpace.
Primary seven-year data from Janssen’s (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.
In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs. ZS Associates’ Maria Whitman provides analyses and tips.
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
Amylyx Pharmaceuticals shared news that the FDA has extended the review period for AMX0035, a combination drug treatment with the potential to treat patients with ALS.
The results showed that insulin icodec is as non-inferior to Sanofi’s insulin glargine, Lantus, potentially bringing another major competitor into the insulin space.
The FDA has expressed worries over four cases of heart inflammation, or myocarditis, that were observed in pivotal clinical trials of Novavax’s COVID-19 vaccine.
Acelyrin, Affibody AB and Inmagene Biopharmaceuticals presented positive Phase II data for izokibep in psoriatic arthritis, while Aurinia’s Lupkynis hit post-hoc treatment targets in lupus nephritis.